Positive DEP Cabazitaxel Phase 2 Results in Multiple Cancer
Filed with ASX · · 8 pages · English
Starpharma Holdings Limited on 6ix
Story so far
Earlier from Starpharma
- DEP irinotecan clinical data presented at AACR meeting
- DEP irinotecan combination data presentation
- VIRALEZ UK COVID-19 Clinical Study Completes Recruitment
- Positive DEP irinotecan clinical results presentation
- App 4E/Annual Report to shareholders
Later from Starpharma
- Starpharma receives $7.2 million R&D Tax Incentive refund
- Starpharma announces new CEO, Ms Cheryl Maley
- AGM Chairman's address and CEO presentation
- Positive DEP docetaxel Phase 2 results
- VivaGel BV sales and distribution agreement MENA region
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma